Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1949 1
1955 1
1956 1
1958 1
1960 1
1961 1
1962 1
1963 2
1964 1
1965 1
1966 1
1968 1
1969 1
1971 3
1972 3
1973 7
1974 12
1975 24
1976 34
1977 42
1978 42
1979 47
1980 45
1981 56
1982 55
1983 52
1984 46
1985 59
1986 50
1987 38
1988 55
1989 68
1990 70
1991 81
1992 87
1993 104
1994 87
1995 102
1996 98
1997 111
1998 98
1999 124
2000 134
2001 158
2002 148
2003 152
2004 158
2005 212
2006 239
2007 203
2008 214
2009 261
2010 287
2011 323
2012 309
2013 333
2014 335
2015 322
2016 283
2017 257
2018 256
2019 309
2020 329
2021 340
2022 342
2023 290
2024 146

Text availability

Article attribute

Article type

Publication date

Search Results

7,290 results

Results by year

Filters applied: . Clear all
Page 1
The three Es of cancer immunoediting.
Dunn GP, Old LJ, Schreiber RD. Dunn GP, et al. Among authors: schreiber rd. Annu Rev Immunol. 2004;22:329-60. doi: 10.1146/annurev.immunol.22.012703.104803. Annu Rev Immunol. 2004. PMID: 15032581 Free article. Review.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Hanauer SB, et al. Among authors: schreiber s. Lancet. 2002 May 4;359(9317):1541-9. doi: 10.1016/S0140-6736(02)08512-4. Lancet. 2002. PMID: 12047962 Clinical Trial.
BACKGROUND: We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab. METHODS: 573 patients with a score of at least 220 on the Crohn's disease …
BACKGROUND: We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's …
Schroth Physiotherapeutic Scoliosis-Specific Exercise (PSSE) Trials-Systematic Review of Methods and Recommendations for Future Research.
Schreiber S, Whibley D, Somers EC. Schreiber S, et al. Children (Basel). 2023 May 27;10(6):954. doi: 10.3390/children10060954. Children (Basel). 2023. PMID: 37371186 Free PMC article. Review.
Eligible studies (n = 7) were conducted in six countries and included patients with Scheuermann's kyphosis (n = 1) and adolescent idiopathic scoliosis (n = 6). ...
Eligible studies (n = 7) were conducted in six countries and included patients with Scheuermann's kyphosis (n = 1) and adolescent idi …
Development of the Crohn's disease digestive damage score, the Lemann score.
Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. Pariente B, et al. Among authors: schreiber s. Inflamm Bowel Dis. 2011 Jun;17(6):1415-22. doi: 10.1002/ibd.21506. Epub 2010 Nov 28. Inflamm Bowel Dis. 2011. PMID: 21560202 Free PMC article.
Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure disease activity at a specific point in time. ...The project is being conducted by the International Program to develop New Indexes in Crohn's disease (IPNIC) …
Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure disease activity at a spec …
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. Feagan BG, et al. Among authors: schreiber s. Lancet. 2017 Apr 29;389(10080):1699-1709. doi: 10.1016/S0140-6736(17)30570-6. Epub 2017 Apr 12. Lancet. 2017. PMID: 28411872 Free article. Clinical Trial.
Eligible patients were aged 18-75 years, with a diagnosis of Crohn's disease for at least 3 months, assessed as moderate-to-severe Crohn's disease at screening, defined as a Crohn's Disease Activity Index (CDAI) of 220-450, with mucosal ulcers in the ileum or …
Eligible patients were aged 18-75 years, with a diagnosis of Crohn's disease for at least 3 months, assessed as moderate-to-severe Cr …
Uncoupling Pain and Opioid Use after Surgery.
Shiraz Ladha K, Schreiber KL. Shiraz Ladha K, et al. Among authors: schreiber kl. Anesthesiology. 2023 May 1;138(5):457-459. doi: 10.1097/ALN.0000000000004552. Anesthesiology. 2023. PMID: 37039713 Free article. No abstract available.
Albumin synthesis.
Rothschild MA, Oratz M, Schreiber SS. Rothschild MA, et al. Among authors: schreiber ss. Int Rev Physiol. 1980;21:249-74. Int Rev Physiol. 1980. PMID: 6993396 Review. No abstract available.
The Search for Our Identity.
Schreiber J, Richards M. Schreiber J, et al. J Am Acad Child Adolesc Psychiatry. 2023 May;62(5):601. doi: 10.1016/j.jaac.2023.01.008. Epub 2023 Jan 25. J Am Acad Child Adolesc Psychiatry. 2023. PMID: 36708922
Identity has been a part of psychiatry from its roots. Sigmund Freud's description of the id, ego, and super ego reflects the various identities that lie within each of us. ...The discussion of identity development through our experiences and how we view our current identi …
Identity has been a part of psychiatry from its roots. Sigmund Freud's description of the id, ego, and super ego reflects the various …
Meta-analysis of published cerebrospinal fluid proteomics data identifies and validates metabolic enzyme panel as Alzheimer's disease biomarkers.
van Zalm PW, Ahmed S, Fatou B, Schreiber R, Barnaby O, Boxer A, Zetterberg H, Steen JA, Steen H. van Zalm PW, et al. Among authors: schreiber r. Cell Rep Med. 2023 Apr 18;4(4):101005. doi: 10.1016/j.xcrm.2023.101005. Cell Rep Med. 2023. PMID: 37075703 Free PMC article.
To develop therapies for Alzheimer's disease, we need accurate in vivo diagnostics. Multiple proteomic studies mapping biomarker candidates in cerebrospinal fluid (CSF) resulted in little overlap. ...This resulting 3-protein biomarker panel differentiates Alzheimer's …
To develop therapies for Alzheimer's disease, we need accurate in vivo diagnostics. Multiple proteomic studies mapping biomarker cand …
7,290 results